請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71570
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Po-Hsun Chang | en |
dc.contributor.author | 張博勛 | zh_TW |
dc.date.accessioned | 2021-06-17T06:03:32Z | - |
dc.date.available | 2021-03-05 | |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-01-28 | |
dc.identifier.citation | 1. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2015. CA: a cancer journal for clinicians 2015, 65, 5-29.
2. McCubrey, J. A.; Abrams, S. L.; Fitzgerald, T. L.; Cocco, L.; Martelli, A. M.; Montalto, G.; Cervello, M.; Scalisi, A.; Candido, S.; Libra, M., Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in biological regulation 2015, 57, 75-101. 3. Martelotto, L. G.; Ng, C. K.; Piscuoglio, S.; Weigelt, B.; Reis-Filho, J. S., Breast cancer intra-tumor heterogeneity. Breast Cancer Research 2014, 16, 210. 4. Geck, R. C.; Toker, A., Nonessential amino acid metabolism in breast cancer. Advances in biological regulation 2016, 62, 11-17. 5. Semenza, G. L., The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2016, 1863, 382-391. 6. Kizaka‐Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M., Tumor hypoxia: a target for selective cancer therapy. Cancer science 2003, 94, 1021-1028. 7. McKeown, S., Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response. The British journal of radiology 2014, 87, 20130676. 8. Semenza, G. L., Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in pharmacological sciences 2012, 33, 207-214. 9. Brahimi-Horn, M. C.; Pouysségur, J., Hypoxia in cancer cell metabolism and pH regulation. Essays in biochemistry 2007, 43, 165-178. 10. Comerford, K. M.; Wallace, T. J.; Karhausen, J.; Louis, N. A.; Montalto, M. C.; Colgan, S. P., Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer research 2002, 62, 3387-3394. 11. Mayer, A.; Vaupel, P., Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? In Oxygen Transport to Tissue XXXV, Springer: 2013; pp 203-209. 12. Kagiya, G.; Ogawa, R.; Choudhuri, R.; Cook, J. A.; Hatashita, M.; Tanaka, Y.; Koda, K.; Yamashita, K.; Kubo, M.; Kawakami, F., Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression. Oncology reports 2015, 34, 1065-1073. 13. Yoon, C.; Lee, H.; Park, D.; Lee, Y.; Tap, W.; Eisinger-Mathason, T.; Hart, C.; Choy, E.; Simon, M.; Yoon, S., Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. British journal of cancer 2015, 113, 46. 14. Wouters, B.; Weppler, S.; Koritzinsky, M.; Landuyt, W.; Nuyts, S.; Theys, J.; Chiu, R.; Lambin, P., Hypoxia as a target for combined modality treatments. European Journal of Cancer 2002, 38, 240-257. 15. Doleschel, D.; Rix, A.; Arns, S.; Palmowski, K.; Gremse, F.; Merkle, R.; Salopiata, F.; Klingmüller, U.; Jarsch, M.; Kiessling, F., Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion. Theranostics 2015, 5, 905. 16. Zheng, R.; Yao, Q.; Xie, G.; Du, S.; Ren, C.; Wang, Y.; Yuan, Y., TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkinmediated mitophagy. Oncotarget 2015, 6, 17417. 17. Splith, K.; Bergmann, R.; Pietzsch, J.; Neundorf, I., Specific Targeting of Hypoxic Tumor Tissue with Nitroimidazole–Peptide Conjugates. ChemMedChem 2012, 7, 57-61. 18. Griffith, L. G.; Swartz, M. A., Capturing complex 3D tissue physiology in vitro. Nature reviews Molecular cell biology 2006, 7, 211. 19. DesRochers, T. M.; Palma, E.; Kaplan, D. L., Tissue-engineered kidney disease models. Advanced drug delivery reviews 2014, 69, 67-80. 20. Olive, P. L.; Durand, R. E., Detection of hypoxic cells in a murine tumour with the use of the comet assay. JNCI: Journal of the National Cancer Institute 1992, 84, 707-711. 21. Hutmacher, D. W.; Horch, R. E.; Loessner, D.; Rizzi, S.; Sieh, S.; Reichert, J. C.; Clements, J. A.; Beier, J. P.; Arkudas, A.; Bleiziffer, O., Translating tissue engineering technology platforms into cancer research. Journal of cellular and molecular medicine 2009, 13, 1417-1427. 22. Katt, M. E.; Placone, A. L.; Wong, A. D.; Xu, Z. S.; Searson, P. C., In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Frontiers in bioengineering and biotechnology 2016, 4, 12. 23. Mehta, G.; Hsiao, A. Y.; Ingram, M.; Luker, G. D.; Takayama, S., Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. Journal of Controlled Release 2012, 164, 192-204. 24. Friedrich, J.; Ebner, R.; Kunz-Schughart, L. A., Experimental anti-tumor therapy in 3-D: spheroids–old hat or new challenge? International journal of radiation biology 2007, 83, 849-871. 25. Gebhard, C.; Gabriel, C.; Walter, I., Morphological and Immunohistochemical characterization of canine Osteosarcoma spheroid cell cultures. Anatomia, histologia, embryologia 2016, 45, 219-230. 26. LaBarbera, D. V.; Reid, B. G.; Yoo, B. H., The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert opinion on drug discovery 2012, 7, 819-830. 27. Goodman, T. T.; Ng, C. P.; Pun, S. H., 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjugate chemistry 2008, 19, 1951-1959. 28. Hsiao, A. Y.; Tung, Y.-C.; Kuo, C.-H.; Mosadegh, B.; Bedenis, R.; Pienta, K. J.; Takayama, S., Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates. Biomedical microdevices 2012, 14, 313-323. 29. Lamichhane, S. P.; Arya, N.; Kohler, E.; Xiang, S.; Christensen, J.; Shastri, V. P., Recapitulating epithelial tumor microenvironment in vitro using three dimensional triculture of human epithelial, endothelial, and mesenchymal cells. BMC cancer 2016, 16, 581. 30. Matte, I.; Legault, C. M.; Garde-Granger, P.; Laplante, C.; Bessette, P.; Rancourt, C.; Piché, A., Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clinical & experimental metastasis 2016, 33, 839-852. 31. Ho, V. H.; Guo, W. M.; Huang, C. L.; Ho, S. F.; Chaw, S. Y.; Tan, E. Y.; Ng, K. W.; Loo, J. S., Manipulating magnetic 3D spheroids in hanging drops for applications in tissue engineering and drug screening. Advanced healthcare materials 2013, 2, 1430-1434. 32. Zanoni, M.; Piccinini, F.; Arienti, C.; Zamagni, A.; Santi, S.; Polico, R.; Bevilacqua, A.; Tesei, A., 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Scientific reports 2016, 6, 19103. 33. Kunz‐Schughart, L., Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell biology international 1999, 23, 157-161. 34. Ingram, M.; Techy, G.; Saroufeem, R.; Yazan, O.; Narayan, K.; Goodwin, T.; Spaulding, G., Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor. In Vitro Cellular & Developmental Biology-Animal 1997, 33, 459-466. 35. Froehlich, K.; Haeger, J.-D.; Heger, J.; Pastuschek, J.; Photini, S. M.; Yan, Y.; Lupp, A.; Pfarrer, C.; Mrowka, R.; Schleußner, E., Generation of multicellular breast cancer tumor spheroids: Comparison of different protocols. Journal of mammary gland biology and neoplasia 2016, 21, 89-98. 36. Ong, S.-M.; Zhao, Z.; Arooz, T.; Zhao, D.; Zhang, S.; Du, T.; Wasser, M.; van Noort, D.; Yu, H., Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 2010, 31, 1180-1190. 37. Wu, L. Y.; Di Carlo, D.; Lee, L. P., Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomedical microdevices 2008, 10, 197-202. 38. Tung, Y.-C.; Hsiao, A. Y.; Allen, S. G.; Torisawa, Y.-s.; Ho, M.; Takayama, S., High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011, 136, 473-478. 39. Kelm, J. M.; Timmins, N. E.; Brown, C. J.; Fussenegger, M.; Nielsen, L. K., Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnology and bioengineering 2003, 83, 173-180. 40. Timmins, N. E.; Nielsen, L. K., Generation of multicellular tumor spheroids by the hanging-drop method. In Tissue Engineering, Springer: 2007; pp 141-151. 41. Lee, W. G.; Ortmann, D.; Hancock, M. J.; Bae, H.; Khademhosseini, A., A hollow sphere soft lithography approach for long-term hanging drop methods. Tissue Engineering Part C: Methods 2009, 16, 249-259. 42. Yuhas, J. M.; Li, A. P.; Martinez, A. O.; Ladman, A. J., A simplified method for production and growth of multicellular tumor spheroids. Cancer research 1977, 37, 3639-3643. 43. Ivascu, A.; Kubbies, M., Rapid generation of single-tumor spheroids for highthroughput cell function and toxicity analysis. Journal of biomolecular screening 2006, 11, 922-932. 44. Lee, J.; Cuddihy, M. J.; Cater, G. M.; Kotov, N. A., Engineering liver tissue spheroids with inverted colloidal crystal scaffolds. Biomaterials 2009, 30, 4687-4694. 45. Godugu, C.; Patel, A. R.; Desai, U.; Andey, T.; Sams, A.; Singh, M., AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PloS one 2013, 8, e53708. 46. Fennema, E.; Rivron, N.; Rouwkema, J.; van Blitterswijk, C.; de Boer, J., Spheroid culture as a tool for creating 3D complex tissues. Trends in biotechnology 2013, 31, 108-115. 47. Jahani, M.; Noroznezhad, F.; Mansouri, K., Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy. Biomedicine & Pharmacotherapy 2018, 102, 594-601. 48. Shen, L.-J.; Shen, W.-C., Drug evaluation: ADI-PEG-20--A PEGylated arginine deiminase for arginine-auxotrophic cancers. Current opinion in molecular therapeutics 2006, 8, 240-248. 49. Ott, P. A.; Carvajal, R. D.; Pandit-Taskar, N.; Jungbluth, A. A.; Hoffman, E. W.; Wu, B.-W.; Bomalaski, J. S.; Venhaus, R.; Pan, L.; Old, L. J., Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational new drugs 2013, 31, 425-434. 50. Yang, T. S.; Lu, S. N.; Chao, Y.; Sheen, I. S.; Lin, C.; Wang, T. E.; Chen, S. C.; Wang, J. H.; Liao, L. Y.; Thomson, J., A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. British journal of cancer 2010, 103, 954. 51. Tsai, H.-J.; Jiang, S. S.; Hung, W.-C.; Borthakur, G.; Lin, S.-F.; Pemmaraju, N.; Jabbour, E.; Bomalaski, J. S.; Chen, Y.-P.; Hsiao, H.-H., A phase II study of arginine deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients. Scientific Reports 2017, 7, 11253. 52. Shen, L.-J.; Beloussow, K.; Shen, W.-C., Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer letters 2006, 231, 30-35. 53. Feun, L.; Savaraj, N., Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert opinion on investigational drugs 2006, 15, 815-822. 54. Wu, F.-L. L.; Liang, Y.-F.; Chang, Y.-C.; Yo, H.-H.; Wei, M.-F.; Shen, L.-J., RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells. Journal of biomedical science 2011, 18, 25. 55. Wu, F.-L. L.; Yeh, T.-H.; Chen, Y.-L.; Chiu, Y.-C.; Cheng, J.-C.; Wei, M.-F.; Shen, L.-J., Intracellular delivery of recombinant arginine deiminase (rADI) by heparinbinding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells. Molecular pharmaceutics 2014, 11, 2777-2786. 56. Desai, N., Challenges in development of nanoparticle-based therapeutics. The AAPS journal 2012, 14, 282-295. 57. Lee, E. S.; Shin, H. J.; Na, K.; Bae, Y. H., Poly (l-histidine)–PEG block copolymer micelles and pH-induced destabilization. Journal of Controlled Release 2003, 90, 363-374. 58. Park, Y.; Park, Y.; Shin, B.; Choi, E.; Park, Y.; Akaike, T.; Cho, C., Galactosylated chitosan–graft–dextran as hepatocyte-targeting DNA carrier. Journal of Controlled Release 2000, 69, 97-108. 59. Gatenby, R. A.; Gillies, R. J., Why do cancers have high aerobic glycolysis? Nature reviews cancer 2004, 4, 891. 60. Warburg, O., On the origin of cancer cells. Science 1956, 123, 309-314. 61. Stubbs, M.; Bashford, C.; Griffiths, J., Understanding the tumor metabolic phenotype in the genomic era. Current molecular medicine 2003, 3, 49-59. 62. Semenza, G. L., Targeting HIF-1 for cancer therapy. Nature reviews cancer 2003, 3, 721. 63. Volk, T.; Jähde, E.; Fortmeyer, H.; Glüsenkamp, K.; Rajewsky, M., pH in human tumour xenografts: effect of intravenous administration of glucose. British journal of cancer 1993, 68, 492. 64. Lee, E. S.; Gao, Z.; Bae, Y. H., Recent progress in tumor pH targeting nanotechnology. Journal of Controlled Release 2008, 132, 164-170. 65. Kim, D.; Gao, Z. G.; Lee, E. S.; Bae, Y. H., In vivo evaluation of doxorubicinloaded polymeric micelles targeting folate receptors and early endosomal pH in drug resistant ovarian cancer. Molecular pharmaceutics 2009, 6, 1353-1362. 66. Fei, L.; Yap, L.-P.; Conti, P. S.; Shen, W.-C.; Zaro, J. L., Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials 2014, 35, 4082-4087. 67. Sun, C.; Shen, W.-C.; Tu, J.; Zaro, J. L., Interaction between cell-penetrating peptides and acid-sensitive anionic oligopeptides as a model for the design of targeted drug carriers. Molecular pharmaceutics 2014, 11, 1583-1590. 68. Sethuraman, V. A.; Na, K.; Bae, Y. H., pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules 2006, 7, 64-70. 69. Viswanathan, A. N.; Schernhammer, E. S., Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer letters 2009, 281, 1-7. 70. Zhou, L.; Yu, L.; Ding, M.; Li, J.; Tan, H.; Wang, Z.; Fu, Q., Synthesis and characterization of pH-sensitive biodegradable polyurethane for potential drug delivery applications. Macromolecules 2011, 44, 857-864. 71. Hofmann, K.; Titus, G.; Montibeller, J. A.; Finn, F. M., Avidin binding of carboxylsubstituted biotin and analogs. Biochemistry 1982, 21, 978-984. 72. Yim, N.; Ryu, S.-W.; Choi, K.; Lee, K. R.; Lee, S.; Choi, H.; Kim, J.; Shaker, M. R.; Sun, W.; Park, J.-H., Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module. Nature communications 2016, 7, 12277. 73. Torchilin, V., Intracellular delivery of protein and peptide therapeutics. Drug Discovery Today: Technologies 2008, 5, e95-e103. 74. Montrose, K.; Yang, Y.; Sun, X.; Wiles, S.; Krissansen, G. W., Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Scientific reports 2013, 3, 1661. 75. Sarker, S. R.; Hokama, R.; Takeoka, S., Intracellular delivery of universal proteins using a lysine headgroup containing cationic liposomes: deciphering the uptake mechanism. Molecular pharmaceutics 2013, 11, 164-174. 76. Han, D. H.; Na, H.-K.; Choi, W. H.; Lee, J. H.; Kim, Y. K.; Won, C.; Lee, S.-H.; Kim, K. P.; Kuret, J.; Min, D.-H., Direct cellular delivery of human proteasomes to delay tau aggregation. Nature communications 2014, 5, 5633. 77. Heitz, F.; Morris, M. C.; Divita, G., Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics. British journal of pharmacology 2009, 157, 195-206. 78. Green, M.; Loewenstein, P. M., Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55, 1179-1188. 79. Farkhani, S. M.; Valizadeh, A.; Karami, H.; Mohammadi, S.; Sohrabi, N.; Badrzadeh, F., Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides 2014, 57, 78-94. 80. Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug discovery today 2012, 17, 850-860. 81. Rothbard, J. B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P. L.; Wender, P. A.; Khavari, P. A., Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nature medicine 2000, 6, 1253. 82. Mo, R. H.; Zaro, J. L.; Shen, W.-C., Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Molecular pharmaceutics 2011, 9, 299-309. 83. Eiríksdóttir, E. a.; Mäger, I.; Lehto, T.; El Andaloussi, S.; Langel, U., Cellular internalization kinetics of (luciferin-) cell-penetrating peptide conjugates. Bioconjugate chemistry 2010, 21, 1662-1672. 84. Sayers, E. J.; Cleal, K.; Eissa, N. G.; Watson, P.; Jones, A. T., Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides. Journal of Controlled Release 2014, 195, 55-62. 85. Sethuraman, V. A.; Bae, Y. H., TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. Journal of Controlled Release 2007, 118, 216-224. 86. Zaro, J. L.; Fei, L.; Shen, W.-C., Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery. Journal of controlled release 2012, 158, 357- 361. 87. Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y., Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proceedings of the National Academy of Sciences 2004, 101, 17867-17872. 88. Aguilera, T. A.; Olson, E. S.; Timmers, M. M.; Jiang, T.; Tsien, R. Y., Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integrative Biology 2009, 1, 371-381. 89. Olson, E. S.; Aguilera, T. A.; Jiang, T.; Ellies, L. G.; Nguyen, Q. T.; Wong, E. H.; Gross, L. A.; Tsien, R. Y., In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integrative Biology 2009, 1, 382-393. 90. Pethe, K.; Alonso, S.; Biet, F.; Delogu, G.; Brennan, M. J.; Locht, C.; Menozzi, F. D., The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412, 190. 91. Shen, W.-C.; Krankel, J.; Likun, F., Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions. Google Patents: 2014. 92. Yeh, T.-H.; Chen, Y.-R.; Chen, S.-Y.; Shen, W.-C.; Ann, D. K.; Zaro, J. L.; Shen, L.-J., Selective intracellular delivery of recombinant arginine deiminase (ADI) using pH-sensitive cell penetrating peptides to overcome ADI resistance in hypoxic breast cancer cells. Molecular pharmaceutics 2015, 13, 262-271. 93. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry 1976, 72, 248-254. 94. Boyde, T.; Rahmatullah, M., Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime. Analytical biochemistry 1980, 107, 424-431. 95. Yang, T.-T.; Sinai, P.; Kain, S. R., An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Analytical biochemistry 1996, 241, 103-108. 96. Clémence, D.; Robin, D.; Pierre, D.; Corinne, A.; Claire, S.; Christelle, B.; Emmanuelle, M.; Frédérique, P.-L.; Bamdad, M., Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. Oncotarget 2017, 8, 95316. 97. Dillon, B. J.; Prieto, V. G.; Curley, S. A.; Ensor, C. M.; Holtsberg, F. W.; Bomalaski, J. S.; Clark, M. A., Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004, 100, 826-833. 98. Qiu, F.; Chen, Y.-R.; Liu, X.; Chu, C.-Y.; Shen, L.-J.; Xu, J.; Gaur, S.; Forman, H. J.; Zhang, H.; Zheng, S., Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci. Signal. 2014, 7, ra31-ra31. 99. Wang, Z.; Shi, X.; Li, Y.; Fan, J.; Zeng, X.; Xian, Z.; Sun, Y.; Wang, S.; Song, P.; Zhao, S., Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell death & disease 2014, 5, e1563. 100. Tang, B.; Zaro, J. L.; Shen, Y.; Chen, Q.; Yu, Y.; Sun, P.; Wang, Y.; Shen, W.-C.; Tu, J.; Sun, C., Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. Journal of Controlled Release 2018, 279, 147-156. 101. Vinci, M.; Gowan, S.; Boxall, F.; Patterson, L.; Zimmermann, M.; Lomas, C.; Mendiola, M.; Hardisson, D.; Eccles, S. A., Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC biology 2012, 10, 29. 102. Wang, J.; Zhang, X.; Li, X.; Zhang, Y.; Hou, T.; Wei, L.; Qu, L.; Shi, L.; Liu, Y.; Zou, L., Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. Scientific reports 2016, 6, 24772. 103. Jackson, J. P.; Li, L.; Chamberlain, E. D.; Wang, H.; Ferguson, S. S., Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG® Cell Cultures. Drug Metabolism and Disposition 2016, dmd. 116.069831. 104. Costa, E. C.; Moreira, A. F.; de Melo-Diogo, D.; Gaspar, V. M.; Carvalho, M. P.; Correia, I. J., 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnology advances 2016, 34, 1427-1441. 105. Mikhail, A. S.; Eetezadi, S.; Allen, C., Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere® . PloS one 2013, 8, e62630. 106. Friedrich, J.; Seidel, C.; Ebner, R.; Kunz-Schughart, L. A., Spheroid-based drug screen: considerations and practical approach. Nature protocols 2009, 4, 309. 107. Baek, N.; Seo, O. W.; Kim, M.; Hulme, J.; An, S. S. A., Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time. OncoTargets and therapy 2016, 9, 7207. 108. Zhang, W.; Li, C.; Baguley, B. C.; Zhou, F.; Zhou, W.; Shaw, J. P.; Wang, Z.; Wu, Z.; Liu, J., Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model. Analytical biochemistry 2016, 515, 47-54. 109. Dos Santos, F. A.; Pereira, M. C.; de Oliveira, T. B.; Mendonça Junior, F. J. B.; de Lima, M. d. C. A.; Pitta, M. G. d. R.; Pitta, I. d. R.; de Melo, R.; Barreto, M. J.; da Rocha, P., Anticancer properties of thiophene derivatives in breast cancer MCF-7 cells. Anti-cancer drugs 2018, 29, 157-166. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71570 | - |
dc.description.abstract | 由於腫瘤細胞的異型性使單層細胞模型與真實人體腫瘤的差異性增大,因此目前的2D細胞培養模型並不足以用來預測人體的生理狀況。為了縮小體外試驗與活體試驗的差異性,發展與人體具有生理相似性的體外3D細胞培養模型在近年來受到了愈來愈多的關注。本研究以人類乳腺癌MCF-7與MDA-MB-231細胞,建立體外3D細胞培養模型,並利用兩株乳腺癌細胞不同的特性,比較其在3D和2D細胞培養模型對所製備之蛋白質藥物ADI與HBHAc-HE-ADI的敏感性差異。期望能以更接近人體內腫瘤真實狀況的體外3D細胞培養模型,了解所製備藥物之發展與應用的可行性。在藥物製備部分,以轉型作用將ADI及HBHAc-HE-ADI之質體送入E.coli BL21,藉由定序確認基因序列正確性後,以2X YT medium培養並加入IPTG使菌體大量表現蛋白,離心後將菌體打破以取得內涵體並溶出蛋白,經重新摺疊、濃縮、純化並透析等步驟後獲得ADI及HBHAc-HE-ADI,並以SDS-PAGE及Western Blots確認其正確性,再經Bradford protein assay定量,並以ADI activity assay測得其活性分別可達259及177 mU/mg。在2D細胞培養模型試驗部分,設計不同pH及氧氣濃度之差異,並以MCF-7及MDA-MB-231此二細胞株相互比較,結果顯示:MDA-MB-231 與MCF-7相比,不論在不同pH或氧氣濃度下皆對ADI及HBHAc-HE-ADI更具敏感性;而HBHAc-HE-ADI與ADI相比,在不同pH及不同氧氣濃度下對兩細胞株之效果皆無顯著差異。在建立3D細胞培養模型部分,以非貼附型培養法並比較不同加入胞外基質方式,培養出均質的MCF-7及MDA-MB-231腫瘤球;接著藉由測量不同細胞密度所形成之腫瘤球的直徑大小,選定適合之起始細胞濃度,並測量不同天之代謝活性,綜合比較腫瘤球的外型、直徑與代謝活性後選定最適合之給藥日。在3D細胞培養模型試驗部分,MDA-MB-231及MCF-7腫瘤球對ADI及HBHAc-HE-ADI皆具有好的抗性,在0.001至10 mU/mL劑量間的細胞存活率皆無顯著差異,測量腫瘤球在給藥期間的直徑大小亦無變化,顯示出3D與2D細胞培養模型對藥物之敏感性具有一定程度之差異。本研究所建立起之3D細胞培養模型,在未來亦可應用於其它藥物之篩選開發,作為藥物由2D細胞培養模型試驗進入活體試驗前的橋樑。 | zh_TW |
dc.description.abstract | The differences between a monolayer cell culture and spheroids in human come from the heterogeneity of spheroids. Thus, current 2D cell culture is not enough to be an ideal model for predicting physiological conditions in human bodies. To make the difference between in vitro and in vivo assays smaller, the development of 3D in vitro cell culture which is similar to human body has drawn more and more attentions in recent years. This study built up 3D in vitro cell cultures of MCF-7 and MDA-MB-231 breast cancer cells and compared the differences of sensitivity to the protein drugs we prepared, ADI and HBHAc-HE-ADI, between 2D and 3D cell cultures. We would like to know the possibility of development and application of the drugs prepared in this study by a 3D in vitro cell culture which is more similar to spheroids in human body. On the part of drug preparation, we transformed the plasmid of ADI and HBHAc-HE-ADI into E.coli BL21. After confirming the sequences were correct, we cultivated the bacteria by 2X YT medium and added IPTG to make them express the protein in a large amount. The pellets were centrifuged and lysed to get the inclusion bodies. Then the proteins were soluted out and went through the steps of refolding, condensing, purification and dialysis. Finally, we got the ADI and HBHAc-HE-ADI. We confirmed the correctness of them by SDS-PAGE and western blots, and used Bradford protein assay to quantify the amount of proteins. With ADI activity assay, we knew the unit activity of ADI and HBHAc-HE-ADI were 259 and 177 mU/mg, respectively. On the part of 2D cell culture assays, we design different pH and oxygen concentrations in each group and compared the differences between MCF-7 and MDA-MB-231. The results showed that MDA-MB-231 was more sensitive to ADI and HBHAc-HE-ADI than MCF-7 either at different pH or oxygen concentrations, and no significant differences between the effects of HBHAc-HE-ADI and ADI on two cell cultures were found at different pH and oxygen concentrations. On the part of building up the 3D cell cultures, non-adherent culture was used and different methods of adding excellular matrix were compared in order to form up homogeneous MCF-7 and MDA-MB-231 spheroids. After measuring the diameter of spheroids formed by different seeding cells, the most appropriate seeding cell density was chosen and the metabolic activity of them at different days were measured. Finally, the dosing day was chosen after taking the morphology, diameter, and metabolic activity of spheroids into account. On the part of 3D cell culture assays, both MDA-MB-231 and MCF-7 spheroids showed resistance to ADI and HBHAc-HE-ADI that their cell viability had no significant differences between the doses ranged from 0.001 to 10 mU/mL. Also, the diameter of spheroids didn’t change during drug administration. These results showed that the sensitivity to drugs was different between 3D and 2D cell cultures. The 3D cell culture models built up in this study can be applied to the screening and development of other drugs, which would be a link between 2D cell culture assays and in vivo assays. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:03:32Z (GMT). No. of bitstreams: 1 ntu-108-R05423009-1.pdf: 3795829 bytes, checksum: 3979e76366387bffd254478433d8060d (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄
目錄 .................................................................................................................................. I 圖目錄 ............................................................................................................................ IV 附錄目錄 ........................................................................................................................ VI 縮寫表 ...........................................................................................................................VII 摘要 ..............................................................................................................................VIII Abstract............................................................................................................................X 第一章 文獻回顧.......................................................................................................... 1 1.1 乳癌治療......................................................................................................... 1 1.2 缺氧環境對癌症進展與藥物治療的影響..................................................... 1 1.3 3D 細胞培養模型與癌症研究....................................................................... 2 1.4 精胺酸與基因重組精胺酸去亞胺酶(Arginine deiminase, ADI)............. 4 1.5 主動標靶遞送................................................................................................. 4 1.6 蛋白質藥物的胞內運輸................................................................................. 5 1.6.1 細胞穿透胜肽...................................................................................... 6 1.6.1.1 肝素結合凝血附著素胜肽c .................................................... 7 第二章 研究目的.......................................................................................................... 8 第三章 實驗材料........................................................................................................ 10 3.1 製備基因重組精氨酸去亞胺酶................................................................... 10 3.2 細胞培養........................................................................................................11 3.3 3D 細胞培養模型建立..................................................................................11 3.4 細胞存活分析............................................................................................... 12 3.5 蛋白質濃度測量........................................................................................... 12 第四章 實驗方法........................................................................................................ 13 4.1 ADI 與HBHAc-HE-ADI 的製備................................................................. 13 4.1.1 重組DNA 質體的轉型作用與定序................................................. 13 4.1.2 重組蛋白表現與純化........................................................................ 13 4.2 蛋白質藥物定性與定量測定....................................................................... 14 4.2.1 純度分析............................................................................................ 14 4.2.2 蛋白濃度測定.................................................................................... 14 4.2.3 ADI 活性測定(ADI activity assay) .............................................. 15 4.3 細胞培養(Cell culture) ............................................................................ 15 4.3.1 2D 細胞培養...................................................................................... 15 4.3.2 3D 細胞培養模型建立...................................................................... 16 4.4 細胞存活率試驗(Cell viability assay) .................................................... 16 4.4.1 2D 細胞培養模型.............................................................................. 16 4.4.1.1 不同pH 環境.......................................................................... 17 4.4.1.2 常氧與缺氧環境..................................................................... 17 4.4.2 3D 細胞培養模型.............................................................................. 17 4.5 腫瘤生長抑制............................................................................................... 18 4.6 統計分析....................................................................................................... 18 第五章 實驗結果........................................................................................................ 19 5.1 表現質體的確認與重組蛋白的純化........................................................... 19 5.2 蛋白質藥物定性與定量測定....................................................................... 20 5.3 ADI 與HBHAc-HE-ADI 對乳腺癌細胞之生長抑制效果......................... 20 5.4 3D 細胞模型建立......................................................................................... 23 5.4.1 MCF-7 之3D 細胞模型.................................................................... 23 5.4.2 MDA-MB-231 之3D 細胞模型........................................................ 24 5.5 對3D 細胞作用之存活率分析與腫瘤抑制效果........................................ 25 5.5.1 對MCF-7 作用之存活率.................................................................. 25 5.5.2 對MDA-MB-231 作用之存活率與腫瘤抑制效果.......................... 26 第六章 討論................................................................................................................ 27 6.1 MCF-7 與MDA-MB-231 兩細胞株之差異性............................................ 27 6.2 ADI 與HBHAc-HE-ADI 之差異性............................................................. 28 6.3 3D 細胞培養模型之建立............................................................................. 29 6.4 對3D 細胞培養模型投藥日之選擇............................................................ 30 6.5 2D 與3D 細胞培養模型之差異.................................................................. 32 6.6 實驗限制....................................................................................................... 33 第七章 結論................................................................................................................ 34 第八章 參考文獻........................................................................................................ 62 | |
dc.language.iso | zh-TW | |
dc.title | 重組精胺酸脫亞胺酶及其含穿胞胜肽HBHAc-HE修飾劑型分別於乳腺癌2D 與3D細胞培養模型的效果研究 | zh_TW |
dc.title | Study on the effects of recombinant arginine deiminase and its modified form with a cell-penetrating peptide HBHAc-HE, in 2D and 3D cell cultures, respectively, of breast cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 孔繁璐,許麗卿 | |
dc.subject.keyword | 精胺酸去亞胺?,3D細胞培養,腫瘤球,乳腺癌,細胞穿透胜?, | zh_TW |
dc.subject.keyword | arginine deiminase,3D cell culture,spheroids,breast cancer,cell-penetrating peptide, | en |
dc.relation.page | 75 | |
dc.identifier.doi | 10.6342/NTU201900219 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-01-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。